As has been the case for a number of years, the diabetes market remains quite active with ongoing research and the development of products designed to help the large patient population afflicted with the condition. However, the focus of that activity has shifted a bit as device manufacturers work to refine connectivity issues of their products, an issue that has become important in this burgeoning age of digital health. Additionally, efforts to get a fully automated artificial pancreas (AP) to market continue to make important steps forward, and it is possible the first such product could be available within two or three years. (SeeAlso see "ADA 2014: Diabetes Players Move Closer To An Artificial Pancreas" - Medtech Insight, 14 August, 2014.andAlso see "The Digital Health Care Revolution Picks Up Speed" - Medtech Insight, 14 July, 2015..)
When looking at connectivity and AP development, the industry’s eyes usually turn to two important players, Medtronic PLCand DexCom Inc., companies that have taken different routes to their current leadership positions. Medtronic is a large corporation with worldwide earnings of $20.3 billion for the company’s recently closed 2015 fiscal year, and $1.76 billion in its diabetes division for the same period. Additionally, the company has been associated with diabetes care since it rolled out its first external insulin pump, the MiniMed 502, in 1983
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?